Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma

Seogsong Jeong; Woo-Young Shin; Yun Hwan Oh

doi:10.3389/fendo.2023.1150360

Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma

Front Endocrinol (Lausanne). 2023 Mar 20:14:1150360. doi: 10.3389/fendo.2023.1150360. eCollection 2023.

Authors

Seogsong Jeong^{1

2}, Woo-Young Shin³, Yun Hwan Oh³

Affiliations

¹ Department of Biomedical Informatics, CHA University School of Medicine, CHA University, Seongnam, Republic of Korea.
² Institute for Biomedical Informatics, School of Medicine, CHA University, Seongnam, Republic of Korea.
³ Department of Family medicine, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, Republic of Korea.

Abstract

The progression of non-alcoholic fatty liver disease (NAFLD), the most common liver disease, leads to non-alcoholic steatohepatitis and hepatocellular carcinoma. Despite the increasing incidence and prevalence of NAFLD, its therapeutic and preventive strategies to lower the disease burden is limited. In recent years, immunotherapy, including anti-programmed cell death 1/programmed cell death 1 ligand 1 treatment, has emerged as a potential approach to reach satisfactory modulation for the progression of NAFLD and treatment of NAFLD-related hepatocellular carcinoma. However, the effectiveness of immunotherapy against NAFLD and NAFLD-related hepatocellular carcinoma is in the early phase and it is yet not advanced. In addition, conflicting results are being reported regarding the prognosis of patients with NAFLD-related hepatocellular carcinoma and high expression of programmed cell death 1/programmed cell death 1 ligand 1. Herein, this review will discuss and elucidate the attempts and underlying mechanisms of immunotherapy against NAFLD and NAFLD-related hepatocellular carcinoma.

Keywords: chronic liver disease; immune system; immunity; liver cancer; non-alcoholic fatty liver disease.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

B7-H1 Antigen
Carcinoma, Hepatocellular* / pathology
Humans
Immunotherapy
Liver Neoplasms* / pathology
Non-alcoholic Fatty Liver Disease* / metabolism

Substances

B7-H1 Antigen

Grants and funding

This research was funded by the Korean Academy of Menopause and Andropause (2023).